Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B

NCT07589400 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolic Dysfunction-associated Steatotic Liver Disease
Chronic Hepatitis b

Interventions

DRUG: ACT500 Tablets
DRUG: ACT500 Tablets
DRUG: ACT500 Tablets
DRUG: ACT500 Placebo Tablets
DRUG: ACT500 Placebo Tablets
DRUG: ACT500 Placebo Tablets

Sponsor

Xiamen Amoytop Biotech Co., Ltd.